Extracellular vesicles (EVs): A promising therapeutic tool in the heart tissue regeneration

Abstract

AbstractMesenchymal stem cells (MSCs) treatment has been widely explored as a therapy for myocardial infarction, peripheral ischemic vascular diseases, dilated cardiomyopathy, and pulmonary hypertension. Latest in vitro studies suggest that MSCs can differentiate into contractile cardiomyocytes. One of the best‐characterized MSCs products are MSCs‐derived extracellular vesicles (EVs). EVs are crucial paracrine effectors of MSCs. Based on previous works, paracrine effects of MSCs play a primary role in the regenerative ability. Hence, in the current paper, we focused our attention on an alternative approach, exploiting products derived from human dental pulp stem cells (hDPSCs) rather than MSCs themselves, which may denote a cost‐effective and safer approach. The focus has been on EVs and the bioactive molecules they contain to evaluate their ability to influence the differentiation process toward cardiomyogenic lineage. The expression of GATA4, ACTC1, CX43, and Nkx2.5 was evaluated using Immunofluorescence, real time‐PCR, and Western blotting analyses. Furthermore, the expression profiling analysis of the microRNA hsa‐miR‐200c‐3p, targeting the GATA4 gene, was studied. The hsa‐miR‐200c‐3p was found significantly down‐regulated in both c‐hDPSCs + EVs‐hDPSCs and c‐hDPSCs + EVs‐HL‐1 compared to untreated c‐hDPSCs underlying a possible epigenetic mechanism behind the prevalent up‐regulation of its targeted GATA4 gene. The aim of the present work was to develop an in vitro model of hDPSCs able to differentiate into cardiomyocytes in order to investigate the role of EVs derived from hDPSCs and derived from HL‐1 cardiomyocyte cell line in modulating the differentiation process toward cardiomyogenic lineage.